Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
3/A

An amendment to a 3 filing. Non-EDGAR filing

 View HTML
0001415889-22-003505.pdf
0001415889-22-003505.rtf
0001415889-22-003505.xls
4/A

Amendment to a previously filed 4

 View HTML
0001415889-22-003506.pdf
0001415889-22-003506.rtf
0001415889-22-003506.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-003280.pdf
0001415889-22-003280.rtf
0001415889-22-003280.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-003186.pdf
0001415889-22-003186.rtf
0001415889-22-003186.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002923.pdf
0001415889-22-002923.rtf
0001415889-22-002923.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002735.pdf
0001415889-22-002735.rtf
0001415889-22-002735.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002732.pdf
0001415889-22-002732.rtf
0001415889-22-002732.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002734.pdf
0001415889-22-002734.rtf
0001415889-22-002734.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002733.pdf
0001415889-22-002733.rtf
0001415889-22-002733.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002739.pdf
0001415889-22-002739.rtf
0001415889-22-002739.xls